Literature DB >> 12930365

Increased numbers of CD38 molecules on bright CD8+ T lymphocytes in infectious mononucleosis caused by Epstein-Barr virus infection.

S Zidovec Lepej1, A Vince, O Dakovic Rode, A Remenar, T Jeren.   

Abstract

The aim of this study was to quantify the expression of CD38 on CD8+ T lymphocytes of patients with infectious mononucleosis (IM) caused by Epstein-Barr virus (EBV) and cytomegalovirus (CMV). CD38 quantification technique chosen for this study was based on the enumeration of CD38 antibody binding sites in comparison to the quantification standards rather than determining relative fluorescence, which is difficult to standardize. The study enrolled 19 patients with typical clinical and laboratory parameters compatible with EBV-induced IM as well as 10 patients with atypical clinical presentation of this disease. Furthermore, CD38 expression was analysed in a group of 13 patients with IM caused by CMV infection. CD38 quantification was performed within 6 days of the presentation of symptoms. All three groups of IM patients showed a statistically significant increase in the number of anti-CD38 antibody binding sites (which correspond to the number of CD38 molecules) on bright CD8+ T lymphocytes compared to healthy controls. The numbers of CD38 molecules expressed on CD8+ T lymphocytes did not differ significantly between IM patients with typical and atypical clinical presentation of the disease. Patients with CMV-induced IM had significantly lower numbers of CD38 molecules expressed on CD8+ T lymphocytes. Therefore, we conclude that CD38 quantification could be helpful in differential diagnostics of IM cases with atypical clinical presentation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12930365      PMCID: PMC1808801          DOI: 10.1046/j.1365-2249.2003.02219.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study.

Authors:  P Bürgisser; C Hammann; D Kaufmann; M Battegay; O T Rutschmann
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

Review 2.  Quantitative flow cytometry.

Authors:  A Schwartz; E Fernández-Repollet
Journal:  Clin Lab Med       Date:  2001-12       Impact factor: 1.935

3.  Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia.

Authors:  Tryfonia Mainou-Fowler; Helen Dignum; Penelope R A Taylor; Anne M Dickinson; Peter W G Saunders; Stephen J Proctor; Geoffrey P Summerfield
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

Review 4.  Flow cytometric quantitation of immunofluorescence intensity: problems and perspectives. European Working Group on Clinical Cell Analysis.

Authors:  J W Gratama; J L D'hautcourt; F Mandy; G Rothe; D Barnett; G Janossy; S Papa; G Schmitz; R Lenkei
Journal:  Cytometry       Date:  1998-10-01

5.  CD8+,CD38+ lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients.

Authors:  A Mocroft; M Bofill; M Lipman; E Medina; N Borthwick; A Timms; L Batista; M Winter; C A Sabin; M Johnson; C A Lee; A Phillips; G Janossy
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-02-01

6.  Changes in the composition of circulating CD8+ T cell subsets during acute epstein-barr and human immunodeficiency virus infections in humans.

Authors:  M T Roos; R A van Lier; D Hamann; G J Knol; I Verhoofstad; D van Baarle; F Miedema; P T Schellekens
Journal:  J Infect Dis       Date:  2000-07-24       Impact factor: 5.226

7.  Expansion of a CD28-intermediate subset among CD8 T cells in patients with infectious mononucleosis.

Authors:  Hiroshi Uda; Toru Mima; Norihiko Yamaguchi; Yoshinori Katada; Masayuki Fukuda; Naohiko Fujii; Kojiro Nakamura; Osamu Saiki
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage.

Authors:  E L Reinherz; P C Kung; G Goldstein; R H Levey; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

9.  Quantitation of CD38 activation antigen expression on CD8+ T cells in HIV-1 infection using CD4 expression on CD4+ T lymphocytes as a biological calibrator.

Authors:  L E Hultin; J L Matud; J V Giorgi
Journal:  Cytometry       Date:  1998-10-01

Review 10.  Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions?

Authors:  A Savarino; F Bottarel; F Malavasi; U Dianzani
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

View more
  11 in total

1.  Chronic Epstein-Barr virus-related hepatitis in immunocompetent patients.

Authors:  Mihaela Petrova; Maria Muhtarova; Maria Nikolova; Svetoslav Magaev; Hristo Taskov; Diana Nikolovska; Zahariy Krastev
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

Review 2.  The CD38 glycohydrolase and the NAD sink: implications for pathological conditions.

Authors:  Julianna D Zeidler; Kelly A Hogan; Guillermo Agorrody; Thais R Peclat; Sonu Kashyap; Karina S Kanamori; Lilian Sales Gomez; Delaram Z Mazdeh; Gina M Warner; Katie L Thompson; Claudia C S Chini; Eduardo Nunes Chini
Journal:  Am J Physiol Cell Physiol       Date:  2022-02-09       Impact factor: 4.249

3.  Virological and immunological characteristics of fatal Epstein-Barr virus mononucleosis in a 17-year-old Caucasian male presenting with meningoencephalitis and hemophagocytic syndrome.

Authors:  Adriana Vince; Snjezana Zidovec Lepej; Ivan Kurelac; Bruno Barsic; Sanja Kozic; Igor Klinar; Kamelia Zarkovic
Journal:  J Neurovirol       Date:  2007-08       Impact factor: 2.643

4.  Peripheral blood lymphocyte counts in patients with infectious mononucleosis or chronic active Epstein-Barr virus infection and prognostic risk factors of chronic active Epstein-Barr virus infection.

Authors:  Jiancheng Lin; Xiaokang Chen; Haiming Wu; Xiaoyun Chen; Xiaomei Hu; Jin Xu
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

5.  T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis.

Authors:  Vandana Chaturvedi; Rebecca A Marsh; Adi Zoref-Lorenz; Erika Owsley; Vijaya Chaturvedi; Trung C Nguyen; Jordana R Goldman; Michael M Henry; Jay N Greenberg; Stephan Ladisch; Michelle L Hermiston; Michael Jeng; Ahmed Naqvi; Carl E Allen; Hector R Wong; Michael B Jordan
Journal:  Blood       Date:  2021-04-29       Impact factor: 25.476

6.  Intermittent and graded exercise effects on NK cell degranulation markers LAMP-1/LAMP-2 and CD8+CD38+ in chronic fatigue syndrome/myalgic encephalomyelitis.

Authors:  Suzanne Broadbent; Rosanne Coutts
Journal:  Physiol Rep       Date:  2017-03

7.  The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections.

Authors:  Eri Katsuyama; Abel Suarez-Fueyo; Sean J Bradley; Masayuki Mizui; Ana V Marin; Lama Mulki; Suzanne Krishfield; Fabio Malavasi; Joon Yoon; Shannan J Ho Sui; Vasileios C Kyttaris; George C Tsokos
Journal:  Cell Rep       Date:  2020-01-07       Impact factor: 9.423

Review 8.  NAD+-consuming enzymes in immune defense against viral infection.

Authors:  Jialin Shang; Michael R Smith; Ananya Anmangandla; Hening Lin
Journal:  Biochem J       Date:  2021-12-10       Impact factor: 3.857

Review 9.  Implications of the NADase CD38 in COVID pathophysiology.

Authors:  Julianna D Zeidler; Sonu Kashyap; Kelly A Hogan; Eduardo Nunes Chini
Journal:  Physiol Rev       Date:  2021-09-08       Impact factor: 37.312

Review 10.  Reversing Post-Infectious Epigenetic-Mediated Immune Suppression.

Authors:  Carlos O Ontiveros; Rosa S Guerra-Resendez; Tomoki Nishiguchi; Malik Ladki; Isaac B Hilton; Larry S Schlesinger; Andrew R DiNardo
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.